Cingulate Inc
CING3.820USD
+0.120+3.24%
Cierre 11/05, 16:00（ET）Cotizaciones retrasadas 15 min
18.68MCap. mercado
PérdidaP/E TTM
Más Datos de Cingulate Inc Compañía
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Información de Cingulate Inc
Símbolo de cotizaciónCING
Nombre de la empresaCingulate Inc
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoMs. Jennifer L. Callahan
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 07
Dirección1901 W. 47Th Place
CiudadKANSAS CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal66205
Teléfono19139422300
Sitio Webhttps://www.cingulate.com/
Símbolo de cotizaciónCING
Fecha de salida a bolsaOct 07, 2021
Director ejecutivoMs. Jennifer L. Callahan
Ejecutivos de Cingulate Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 23 de oct
Actualizado: jue., 23 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Virtu Americas LLC
0.24%
Otro
96.22%
Accionistas
Accionistas
Proporción
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Virtu Americas LLC
0.24%
Otro
96.22%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
1.94%
Corporation
1.81%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.38%
Venture Capital
0.20%
Hedge Fund
0.03%
Otro
95.08%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
40
174.70K
3.12%
-117.92K
2025Q2
44
305.06K
5.93%
+1.66K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Werth Family Investment Associates LLC
97.99K
1.75%
--
--
Aug 01, 2025
The Vanguard Group, Inc.
35.38K
0.63%
+24.62K
+228.78%
Jun 30, 2025
Susquehanna International Group, LLP
33.20K
0.59%
+33.20K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
32.16K
0.57%
+1.76K
+5.78%
Jun 30, 2025
Virtu Americas LLC
13.35K
0.24%
+13.35K
--
Jun 30, 2025
UBS Financial Services, Inc.
12.64K
0.23%
-9.47K
-42.82%
Jun 30, 2025
LPL Financial LLC
12.18K
0.22%
+12.18K
--
Jun 30, 2025
XTX Markets LLC
10.94K
0.2%
+10.94K
--
Jun 30, 2025
Quantum Private Wealth, LLC
10.00K
0.18%
--
--
Jun 30, 2025
BofA Global Research (US)
7.50K
0.13%
+5.54K
+283.09%
Jun 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Fecha
Tipo
Relación
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
